H.B. Fuller Q2: Results Land After Medical-Adhesives Deal Scrutiny

H.B. Fuller released its fiscal second-quarter results slide deck Thursday evening, giving investors the first full look at performance since the stock dropped 8% in April on criticism of its medical-adhesives acquisition.

The presentation, posted after the close, covers the three months through May. The specialty chemicals maker had faced a demand test heading into the quarter: in late April, activist investor Ancora Advisors blasted the $580 million deal for a medical-adhesives unit, arguing it overpaid for a low-margin business. The stock never fully recovered from that selloff.

Thursday’s deck did not include a press release with full financials by the time of publication. The company typically holds its earnings call the following morning. Two earlier AlphaScala pieces flagged that volume trends in H.B. Fuller’s hygiene, packaging, and construction end markets would be the key swing factor. The Ancora row added governance noise on top of the operational question.

H.B. Fuller’s Alpha Score remains unavailable, and the stock is listed as Unscored in AlphaScala’s screening. The company operates in basic materials, competing with Henkel and Bostik. Investors tracking the Q2 print will look for organic growth rates, margin recovery, and any updated full-year guidance. The earnings call is expected Friday morning.